Like many biotech entrepreneurs in the late 1990s, Randy Scott, then at Incyte Genomics, and George Poste of SmithKline Beecham believed that sequencing the human genome held great promise for developing new medicines. But a faster route to translating genomic data into profits, they thought, would be to focus initially on finding biomarkers predictive of disease. So they founded DiaDexus in September 1997, and with $25 million in start-up funds from Incyte and SB, Scott and Poste set out to prove it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.